平台技術開發
The new publication of our self-adjuvanted protein nanoparticle platform VADEX-Pro is published online on Vaccine already. Follow this link for full text: https://authors.elsevier.com/a/1kzU1,60n7vo56
This article is the basis of our future development of a universal vaccine platform. Please looking forward to it!
We have posted the link on our FB page, use the following link to access:
https://www.facebook.com/share/p/14ESY5j238w/
We have filed patent application to protect our intellectual advancement in the tool for Biologic discovery. The well crafted VADEX-pro technology has shown its potential as the essential technology for generating and screening of Ultra-High affinity (KD<1E-12 M) monoclonal antibodies for diagnostic and therapeutic applications. Been a self-adjuvanted protein nanoparticle, VADEX-pro is able to continuously stimulates immune system long after immunization and breaks the binding affinity ceiling that prevents scientists from obtaining ultra-high affinity monoclonal antibodies. Since the binding affinity is closely related to the the specificity of diagnostic and the efficacy of therapeutic monoclonal antibodies, we believe VADEX-pro will serve as an essential tool for the further improvement of human health!
華西亞生醫受邀在美國國家傳染病基金會(NFID)舉辦的年度免疫學研究會議(ACVR)中發表華西亞生醫自行研發的自帶佐劑蛋白質奈米粒子平台技術VADEX-pro, 在免疫學上的功能. 演講題目: 接種VADEX平台合成的蛋白質奈米粒子可刺激超高親和力抗體的生成
https://www.nfid.org/education-events/annual-conference-on-vaccinology-research/